Initiate a Phase 3 study of povorcitinib in hidradenitis suppurativa
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 2 Aug 2022
- Due
- 31 Dec 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Based on findings from the Phase 2 trial, Incyte intends to initiate a Phase 3 study in HS later this year.”
What we found
Evidence strength A What the grades mean
Filings state Incyte initiated two povorcitinib Phase III trials (STOP-HS1 and STOP-HS2) in HS in December 2022, within the deadline month.
-
A Incyte 10-K filed 2023-02-07
“In December 2022, we initiated two Phase III trials (STOP-HS1 and STOP-HS2) in moderate to severe hidradenitis suppurativa.” ✓ confirmed on the page
-
A Incyte 10-Q filed 2023-05-02
“In December 2022, we initiated two Phase III trials (STOP-HS1 and STOP-HS2) in moderate to severe hidradenitis suppurativa.” ✓ confirmed on the page
Market reaction: the shares moved -3.0% against the S&P 500 over the three sessions around the disclosure (6 Feb 2023 to 9 Feb 2023). What this measures
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- Phase 3 study of povorcitinib in hidradenitis suppurativa
- Language
- Aspirational (“aims”, “intends”)
- In the company’s control
- High
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Incyte? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-INCY-005696 · Corrections policy